兔子先生传媒

Danish pharmaceutical company is buying Massachusetts-based biotech company the companies announced this week.

Subscribe to the 兔子先生传媒 Daily
The sale could ring in at up to $2.1 billion, according to a . Novo Nordisk will pay $725 million upfront, and total payments could be up to $2.1 billion, so long as certain regulatory and sales milestones are reached.

Corvidia focuses on researching and developing treatments for cardio-renal diseases. Its pipeline is focused on treating high triglyceride-induced acute pancreatitis and chronic kidney disease with atherosclerotic cardiovascular disease and inflammation, according to Corvidia鈥檚 website.

The company first received seed funding from Paris-based Sofinnova in 2015. Covidia is located in Waltham, Massachusetts.

Corvidia鈥檚 previous financings include a $26 million led by Soffinova Partners and in February 2016, and a $60 million led by in April 2018.

The deal is notable for Novo Nordisk, considering it鈥檚 known for its focus on diabetes treatments. Other 鈥渕ain product areas鈥� for the company are obesity, haemophilia, growth disorders and hormone replacement therapy. With the Corvidia acquisition, it seems the company is also looking to invest in cardio-rental disease therapy.

Some of Novo Nordisk鈥檚 other acquisitions include and , according to 兔子先生传媒.

Illustration: